Mark Pruzanski's most recent trade in Equillium Inc was a trade of 70,000 Director Stock Option (right to buy) done . Disclosure was reported to the exchange on May 28, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Equillium Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2026 | 70,000 | 70,000 | - | - | Director Stock Option (right to buy) | |
| Equillium Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 20,000 | 20,000 | - | - | Director Stock Option (right to buy) | |
| Equillium Inc | Mark Pruzanski | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Feb 2025 | 24,000 | 0 | - | - | Director Stock Option (right to buy) | |
| Equillium Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 24,000 | 24,000 | - | - | Director Stock Option (right to buy) | |
| Equillium Inc | Mark Pruzanski | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Feb 2025 | 20,770 | 0 | - | - | Director Stock Option (right to buy) | |
| Equillium Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 20,770 | 20,770 | - | - | Director Stock Option (right to buy) | |
| Equillium Inc | Mark Pruzanski | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Feb 2025 | 20,000 | 0 | - | - | Director Stock Option (right to buy) | |
| Equillium Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 20,000 | 20,000 | - | - | Director Stock Option (right to buy) | |
| Equillium Inc | Mark Pruzanski | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Feb 2025 | 12,000 | 0 | - | - | Director Stock Option (right to buy) | |
| Equillium Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 12,000 | 12,000 | - | - | Director Stock Option (right to buy) | |
| Equillium Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Equillium Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Equillium Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 17.21 per share. | 30 Nov 2021 | 6,138 | 622,711 (1%) | 0% | 17.2 | 105,635 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.21 per share. | 30 Nov 2021 | 3,817 | 618,894 (1%) | 0% | 17.2 | 65,691 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 16.86 per share. | 29 Oct 2021 | 6,138 | 620,390 (1%) | 0% | 16.9 | 103,487 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.86 per share. | 29 Oct 2021 | 3,817 | 616,573 (1%) | 0% | 16.9 | 64,355 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Grant, award, or other acquisition of securities at price $ 14.85 per share. | 30 Sep 2021 | 6,136 | 618,068 (1%) | 0% | 14.9 | 91,120 | Common Stock |
| Intercept Pharmaceuticals Inc | Mark Pruzanski | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.85 per share. | 30 Sep 2021 | 3,816 | 614,252 (1%) | 0% | 14.9 | 56,668 | Common Stock |